JP2024075713A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024075713A5 JP2024075713A5 JP2024046063A JP2024046063A JP2024075713A5 JP 2024075713 A5 JP2024075713 A5 JP 2024075713A5 JP 2024046063 A JP2024046063 A JP 2024046063A JP 2024046063 A JP2024046063 A JP 2024046063A JP 2024075713 A5 JP2024075713 A5 JP 2024075713A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- formulation according
- amino acid
- acid sequence
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662380652P | 2016-08-29 | 2016-08-29 | |
| US62/380,652 | 2016-08-29 | ||
| PCT/US2017/049211 WO2018044948A1 (en) | 2016-08-29 | 2017-08-29 | Anti-cd3 antibody formulations |
| JP2019531579A JP7057360B2 (ja) | 2016-08-29 | 2017-08-29 | 抗－ｃｄ３抗体製剤 |
| JP2022063973A JP7461401B2 (ja) | 2016-08-29 | 2022-04-07 | 抗－ｃｄ３抗体製剤 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022063973A Division JP7461401B2 (ja) | 2016-08-29 | 2022-04-07 | 抗－ｃｄ３抗体製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024075713A JP2024075713A (ja) | 2024-06-04 |
| JP2024075713A5 true JP2024075713A5 (enExample) | 2024-08-21 |
Family
ID=59858782
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019531579A Active JP7057360B2 (ja) | 2016-08-29 | 2017-08-29 | 抗－ｃｄ３抗体製剤 |
| JP2022063973A Active JP7461401B2 (ja) | 2016-08-29 | 2022-04-07 | 抗－ｃｄ３抗体製剤 |
| JP2024046063A Pending JP2024075713A (ja) | 2016-08-29 | 2024-03-22 | 抗－ｃｄ３抗体製剤 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019531579A Active JP7057360B2 (ja) | 2016-08-29 | 2017-08-29 | 抗－ｃｄ３抗体製剤 |
| JP2022063973A Active JP7461401B2 (ja) | 2016-08-29 | 2022-04-07 | 抗－ｃｄ３抗体製剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US10688186B2 (enExample) |
| EP (2) | EP3504241B1 (enExample) |
| JP (3) | JP7057360B2 (enExample) |
| CN (2) | CN116617387A (enExample) |
| AU (2) | AU2017319318B2 (enExample) |
| CA (1) | CA3032596A1 (enExample) |
| DK (1) | DK3504241T3 (enExample) |
| ES (1) | ES2986900T3 (enExample) |
| IL (2) | IL301948B2 (enExample) |
| WO (1) | WO2018044948A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3504241B1 (en) | 2016-08-29 | 2024-05-15 | Tiziana Life Sciences PLC | Anti-cd3 antibody formulations |
| WO2018226833A1 (en) * | 2017-06-06 | 2018-12-13 | The Brigham And Women's Hospital, Inc. | Methods of suppressing microglial activation |
| EP3488851A1 (en) * | 2018-10-03 | 2019-05-29 | AVM Biotechnology, LLC | Immunoablative therapies |
| AU2019358875B2 (en) * | 2018-10-09 | 2025-08-21 | Monash University | Combination therapy for treatment and prevention of autoimmune and inflammatory diseases |
| JP2022512709A (ja) * | 2018-10-31 | 2022-02-07 | ティジアーナ ライフ サイエンシズ パブリック リミティド カンパニー | 炎症性疾患及び自己免疫疾患を処置する組成物及び方法 |
| KR102503349B1 (ko) | 2019-05-14 | 2023-02-23 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| WO2021035054A1 (en) | 2019-08-20 | 2021-02-25 | Precision Biosciences, Inc. | Lymphodepletion dosing regimens for cellular immunotherapies |
| JP2023517611A (ja) * | 2020-03-10 | 2023-04-26 | ティジアーナ ライフ サイエンシズ パブリック リミティド カンパニー | Ｉｌ－６／ｉｌ－６ｒ抗体の組成物及びその使用方法 |
| GB2595299B (en) | 2020-05-21 | 2022-08-03 | Mabsolve Ltd | Modified immunoglobulin FC regions |
| US12006366B2 (en) | 2020-06-11 | 2024-06-11 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| JP2023535792A (ja) * | 2020-07-30 | 2023-08-21 | ティジアーナ ライフ サイエンシズ パブリック リミティド カンパニー | コロナウイルス治療のための抗ｃｄ３抗体 |
| IL300088A (en) * | 2020-07-31 | 2023-03-01 | Glaxosmithkline Ip Dev Ltd | Antigen binding protein |
| WO2022221767A1 (en) * | 2021-04-16 | 2022-10-20 | Tiziana Life Sciences Plc | Subcutaneous administration of antibodies for the treatment of disease |
| US20230365689A1 (en) * | 2022-05-13 | 2023-11-16 | Tiziana Life Sciences Plc | Nasal formulations of foralumab |
| IL318326A (en) * | 2022-07-27 | 2025-03-01 | Celldex Therapeutics Inc | Anti-Kit Antibody Formulations and Methods |
| KR20250067152A (ko) | 2022-09-09 | 2025-05-14 | 이도르시아 파마슈티컬스 리미티드 | 항-cd3 항체 및 cxcr3 길항제를 포함하는 약학 병용물 |
| AU2024217729A1 (en) | 2023-02-08 | 2025-08-21 | Immunos Therapeutics Ag | FUSION PROTEINS OF ß2 MICROGLOBULIN, HLA HEAVY CHAIN POLYPEPTIDES, AND INHIBITOR OF CD47-SIRPA |
| TW202448505A (zh) | 2023-03-01 | 2024-12-16 | 美商普泛森生技公司 | 用於治療第1型糖尿病的方法及組成物 |
| CN120752054A (zh) | 2023-03-16 | 2025-10-03 | 小野药品工业株式会社 | 抗体制剂 |
| TW202502380A (zh) * | 2023-03-16 | 2025-01-16 | 日商小野藥品工業股份有限公司 | 抗體製劑 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030235583A1 (en) | 2002-06-14 | 2003-12-25 | Jeppe Sturis | Combined use of a modulator of CD3 and a beta cell resting compound |
| US20040037826A1 (en) | 2002-06-14 | 2004-02-26 | Michelsen Birgitte Koch | Combined use of a modulator of CD3 and a GLP-1 compound |
| WO2005048935A2 (en) * | 2003-11-14 | 2005-06-02 | Brigham And Women's Hospital, Inc. | Methods of modulating immunity |
| US20100209437A1 (en) * | 2005-09-12 | 2010-08-19 | Greg Elson | Anti-CD3 Antibody Fromulations |
| AU2007212147A1 (en) * | 2006-02-03 | 2007-08-16 | Medimmune, Llc | Protein formulations |
| EP2007423A2 (en) * | 2006-04-05 | 2008-12-31 | Pfizer Products Incorporated | Ctla4 antibody combination therapy |
| US9308257B2 (en) | 2007-11-28 | 2016-04-12 | Medimmune, Llc | Protein formulation |
| CN102164960A (zh) * | 2008-09-26 | 2011-08-24 | 罗氏格黎卡特股份公司 | 双特异性抗-egfr/抗-igf-1r抗体 |
| WO2010148337A1 (en) * | 2009-06-18 | 2010-12-23 | Wyeth Llc | Lyophilized formulations for small modular immunopharmaceuticals |
| AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
| CA2778334A1 (en) * | 2009-10-20 | 2011-04-28 | Charlotte Mckee | Anti-cd3 antibody dosing in autoimmune disease |
| JP2013508391A (ja) * | 2009-10-20 | 2013-03-07 | グラクソ グループ リミテッド | 体重増加を予防するために抗ｃｄ３抗体を使用する方法 |
| CA2783715A1 (en) | 2009-12-29 | 2011-07-07 | F. Hoffmann-La Roche Ag | Novel antibody formulation |
| WO2012098238A1 (en) * | 2011-01-21 | 2012-07-26 | Novimmune S.A. | Combination therapies and methods using anti-cd3 modulating agents and anti-il-6 antagonists |
| UA118028C2 (uk) * | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування |
| EP3504241B1 (en) | 2016-08-29 | 2024-05-15 | Tiziana Life Sciences PLC | Anti-cd3 antibody formulations |
-
2017
- 2017-08-29 EP EP17765519.8A patent/EP3504241B1/en active Active
- 2017-08-29 EP EP24175798.8A patent/EP4406554A3/en active Pending
- 2017-08-29 CA CA3032596A patent/CA3032596A1/en active Pending
- 2017-08-29 WO PCT/US2017/049211 patent/WO2018044948A1/en not_active Ceased
- 2017-08-29 AU AU2017319318A patent/AU2017319318B2/en active Active
- 2017-08-29 IL IL301948A patent/IL301948B2/en unknown
- 2017-08-29 IL IL264502A patent/IL264502B2/en unknown
- 2017-08-29 US US15/690,192 patent/US10688186B2/en active Active
- 2017-08-29 DK DK17765519.8T patent/DK3504241T3/da active
- 2017-08-29 CN CN202211674110.7A patent/CN116617387A/zh active Pending
- 2017-08-29 ES ES17765519T patent/ES2986900T3/es active Active
- 2017-08-29 CN CN201780052970.8A patent/CN109843920B/zh active Active
- 2017-08-29 JP JP2019531579A patent/JP7057360B2/ja active Active
-
2020
- 2020-05-18 US US16/876,839 patent/US20210000957A1/en not_active Abandoned
-
2022
- 2022-04-07 JP JP2022063973A patent/JP7461401B2/ja active Active
-
2024
- 2024-03-22 JP JP2024046063A patent/JP2024075713A/ja active Pending
- 2024-12-16 AU AU2024278457A patent/AU2024278457A1/en active Pending
-
2025
- 2025-02-07 US US19/048,132 patent/US20250228946A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024075713A5 (enExample) | ||
| JP2022105138A5 (enExample) | ||
| US20110256130A1 (en) | Methods of treating inflammatory disorders | |
| US20010018053A1 (en) | Methods for treating disease states comprising administration of low levels of antibodies | |
| JP6554155B2 (ja) | Ｉｌ−１７アンタゴニストを使用して汎発性膿疱性乾癬（ｇｐｐ）を処置する方法 | |
| JP2020518599A5 (enExample) | ||
| JP2014114288A5 (enExample) | ||
| JP2012505160A (ja) | 炎症を処置する方法 | |
| JP2025032102A5 (enExample) | ||
| JP2017160178A5 (enExample) | ||
| JP2024001125A (ja) | Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法 | |
| JP2020535149A5 (enExample) | ||
| JP2018529661A5 (enExample) | ||
| IL292706A (en) | Type i interferon inhibition in systemic lupus erythematosus | |
| JP2019519584A5 (enExample) | ||
| JP2025069284A5 (enExample) | ||
| CN115697378A (zh) | 用cgrp抑制剂治疗肺部损伤的方法 | |
| CN116712539A (zh) | 抗her2抗体药物偶联物和抗pd-1抗体联合在制备治疗肿瘤的药物中的用途 | |
| JPWO2021123902A5 (enExample) | ||
| JPWO2020186132A5 (enExample) | ||
| RU2019108441A (ru) | Режим дозирования | |
| IL320563A (en) | Anti-c5 antibody fused to factor h for use in the treatment of complement-mediated diseases | |
| WO2022215616A1 (ja) | コロナウイルス感染症治療剤 | |
| JPWO2021186245A5 (enExample) | ||
| Dasenbrook et al. | Anti-inflammatory therapies for cystic fibrosis |